Back to Search
Start Over
Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
- Source :
-
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 31-36. - Publication Year :
- 2021
-
Abstract
- Objectives: Our aim is to evaluate initial efficacy, safety, and durable response of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia (cITP).<br />Methods: This was a retrospective, single-center cohort study including 30 pediatric patients with cITP administered eltrombopag between 1 July 2017 and 1 January 2019. Patients with at least 12 weeks of eltrombopag treatment and available follow-up data were included. Initial response rate, durable response rate, bleeding events, and adverse events were assessed during the follow-up period.<br />Results: The median duration of eltrombopag administration was 6 months (range 3-8 months). The initial response rate was 73.3%. Patients with megakaryocyte count ≥100/slide or Treg <4.5% were more likely to achieve initial response. The median follow-up period was 10 months (range 6-20 months). A total of 53.2% of pediatric patients had a durable response of up to 20 months. Patients with megakaryocyte count ≥100/slide and Treg<4.5% had more than 60% durable response rates compared with individuals with megakaryocyte count<100/slide and Treg≥4.5%, respectively. No serious bleeding events or serious adverse events occurred during the study period.<br />Conclusion: Eltrombopag not only shows excellent initial response but also has continued efficacy and safety. Patients with megakaryocyte count ≥100/slide and Treg<4.5% achieve increased initial response and more frequent durable response.
- Subjects :
- Benzoates adverse effects
Child
Child, Preschool
China epidemiology
Chronic Disease
Female
Humans
Hydrazines adverse effects
Infant
Male
Purpura, Thrombocytopenic, Idiopathic epidemiology
Pyrazoles adverse effects
Receptors, Thrombopoietin agonists
Retrospective Studies
T-Lymphocytes, Regulatory drug effects
Treatment Outcome
Benzoates therapeutic use
Hydrazines therapeutic use
Purpura, Thrombocytopenic, Idiopathic drug therapy
Pyrazoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1607-8454
- Volume :
- 26
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Hematology (Amsterdam, Netherlands)
- Publication Type :
- Academic Journal
- Accession number :
- 33357172
- Full Text :
- https://doi.org/10.1080/16078454.2020.1856511